Johnson & Johnson said AI is cutting by 50% the time needed to generate new leads for drug development. The update points to meaningful efficiency gains in its R&D pipeline, with potential long-term benefits for productivity and innovation. The article is limited to a single operational improvement and is unlikely to materially move the stock on its own.
Johnson & Johnson said AI is cutting by 50% the time needed to generate new leads for drug development. The update points to meaningful efficiency gains in its R&D pipeline, with potential long-term benefits for productivity and innovation. The article is limited to a single operational improvement and is unlikely to materially move the stock on its own.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
